FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2575454267> ?p ?o ?g. }

• W2575454267 endingPage "e162" @default.
• W2575454267 startingPage "e152" @default.
• W2575454267 abstract "The number of targeted oral anticancer medications (TOAMs) has grown rapidly in the past decade. The high cost of TOAMs raises concerns about the financial aspect of treatment, especially for patients enrolled in Medicare Part D plans because of the coverage gap.We identified patients with chronic myeloid leukemia (CML) who were new TOAM users from the SEER registry data linked with Medicare Part D data, from years 2007 to 2012. We followed these patients throughout the calendar year when they started taking the TOAMs and examined their out-of-pocket (OOP) payments and gross drug costs, taking into account their benefit phase, plan type, and cost share group.We found that 726 (81%) of the 898 patients with CML who received TOAMs had reached the catastrophic phase of their Medicare Part D benefit within the year of medication initiation, with a large majority of patients reaching this phase in less than a month. Patients without subsidies showed a clear pattern of a spike in OOP payments when they began treatment with TOAMs. The OOP payment for patients with subsidies was substantially lower. The monthly gross drug costs were similar between patients with and without subsidies.Patients experience quick entry and exit from the coverage gap (also called the donut hole) as a result of the high price of TOAMs. Closing the donut hole will provide financial relief during the initial month(s) of treatment but will not completely eliminate the financial burden." @default.
• W2575454267 created "2017-01-26" @default.
• W2575454267 creator A5003661484 @default.
• W2575454267 creator A5020147975 @default.
• W2575454267 creator A5029035012 @default.
• W2575454267 creator A5071831846 @default.
• W2575454267 date "2017-02-01" @default.
• W2575454267 modified "2023-10-16" @default.
• W2575454267 title "Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications" @default.
• W2575454267 cites W1972362505 @default.
• W2575454267 cites W1976294525 @default.
• W2575454267 cites W1984023073 @default.
• W2575454267 cites W1984959392 @default.
• W2575454267 cites W1998861351 @default.
• W2575454267 cites W2036482755 @default.
• W2575454267 cites W2041837876 @default.
• W2575454267 cites W2050618903 @default.
• W2575454267 cites W2063050425 @default.
• W2575454267 cites W2092164194 @default.
• W2575454267 cites W2093051330 @default.
• W2575454267 cites W2099090260 @default.
• W2575454267 cites W2099354636 @default.
• W2575454267 cites W2105250776 @default.
• W2575454267 cites W2106042291 @default.
• W2575454267 cites W2107779395 @default.
• W2575454267 cites W2113554766 @default.
• W2575454267 cites W2115724268 @default.
• W2575454267 cites W2140974115 @default.
• W2575454267 cites W2153508262 @default.
• W2575454267 cites W2154835844 @default.
• W2575454267 cites W2157008749 @default.
• W2575454267 cites W2164902648 @default.
• W2575454267 cites W2171331269 @default.
• W2575454267 cites W2193292762 @default.
• W2575454267 cites W2402880145 @default.
• W2575454267 cites W2416286649 @default.
• W2575454267 cites W2418898752 @default.
• W2575454267 cites W2513403311 @default.
• W2575454267 cites W2529061634 @default.
• W2575454267 cites W31217916 @default.
• W2575454267 cites W4249759551 @default.
• W2575454267 cites W53781188 @default.
• W2575454267 doi "https://doi.org/10.1200/jop.2016.014639" @default.
• W2575454267 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6366250" @default.
• W2575454267 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28095170" @default.
• W2575454267 hasPublicationYear "2017" @default.
• W2575454267 type Work @default.
• W2575454267 sameAs 2575454267 @default.
• W2575454267 citedByCount "20" @default.
• W2575454267 countsByYear W25754542672017 @default.
• W2575454267 countsByYear W25754542672018 @default.
• W2575454267 countsByYear W25754542672019 @default.
• W2575454267 countsByYear W25754542672020 @default.
• W2575454267 countsByYear W25754542672021 @default.
• W2575454267 countsByYear W25754542672022 @default.
• W2575454267 countsByYear W25754542672023 @default.
• W2575454267 crossrefType "journal-article" @default.
• W2575454267 hasAuthorship W2575454267A5003661484 @default.
• W2575454267 hasAuthorship W2575454267A5020147975 @default.
• W2575454267 hasAuthorship W2575454267A5029035012 @default.
• W2575454267 hasAuthorship W2575454267A5071831846 @default.
• W2575454267 hasBestOaLocation W25754542671 @default.
• W2575454267 hasConcept C10138342 @default.
• W2575454267 hasConcept C126322002 @default.
• W2575454267 hasConcept C144133560 @default.
• W2575454267 hasConcept C145097563 @default.
• W2575454267 hasConcept C160735492 @default.
• W2575454267 hasConcept C162324750 @default.
• W2575454267 hasConcept C2426938 @default.
• W2575454267 hasConcept C2776291444 @default.
• W2575454267 hasConcept C2778729363 @default.
• W2575454267 hasConcept C2778858636 @default.
• W2575454267 hasConcept C2779703844 @default.
• W2575454267 hasConcept C34447519 @default.
• W2575454267 hasConcept C50522688 @default.
• W2575454267 hasConcept C71924100 @default.
• W2575454267 hasConcept C84265765 @default.
• W2575454267 hasConcept C98274493 @default.
• W2575454267 hasConceptScore W2575454267C10138342 @default.
• W2575454267 hasConceptScore W2575454267C126322002 @default.
• W2575454267 hasConceptScore W2575454267C144133560 @default.
• W2575454267 hasConceptScore W2575454267C145097563 @default.
• W2575454267 hasConceptScore W2575454267C160735492 @default.
• W2575454267 hasConceptScore W2575454267C162324750 @default.
• W2575454267 hasConceptScore W2575454267C2426938 @default.
• W2575454267 hasConceptScore W2575454267C2776291444 @default.
• W2575454267 hasConceptScore W2575454267C2778729363 @default.
• W2575454267 hasConceptScore W2575454267C2778858636 @default.
• W2575454267 hasConceptScore W2575454267C2779703844 @default.
• W2575454267 hasConceptScore W2575454267C34447519 @default.
• W2575454267 hasConceptScore W2575454267C50522688 @default.
• W2575454267 hasConceptScore W2575454267C71924100 @default.
• W2575454267 hasConceptScore W2575454267C84265765 @default.
• W2575454267 hasConceptScore W2575454267C98274493 @default.
• W2575454267 hasIssue "2" @default.
• W2575454267 hasLocation W25754542671 @default.
• W2575454267 hasLocation W25754542672 @default.
• W2575454267 hasLocation W25754542673 @default.

• next